023 Numbness, Tingling and Treatment: Making Sense of Neuropathy
Dr Jam & Sally unpack what neuropathy is, why it happens in myeloma treatment, and how patients can recognise, prevent and manage it to protect their quality of life.
📌Key Takeaways:
Know the signs early – tingling, numbness or pain shouldn’t be ignored; speak up before symptoms worsen.
Treatment can be adjusted – modern dosing and combinations make neuropathy less common and more manageable.
You don’t have to live with it – there are effective ways to ease nerve pain and protect your long-term wellbeing.
For extra content and more resources, please visit our website: https://www.themyelomaminutes.com/
This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns
ABOUT YOUR HOSTS
Dr. Jam Kothari
Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity.
Dr. Sally Moore
Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients. She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.
--------
35:30
--------
35:30
022 Remission, Relapse and Reality Understanding the R-Words in Myeloma
Dr Jam & Sally unpack what remission, relapse and refractory disease truly mean for people living with myeloma — and explore how close we are to talking about cure.
📌Key Takeaways:
Remission ≠ cure – myeloma can be controlled for years, even if it never fully disappears.
Monitoring matters – blood tests, bone marrow checks and scans together tell the full story.
Hope is growing – deeper remissions and new tests mean “functional cure” is now within reach.
For extra content and more resources, please visit our website: https://www.themyelomaminutes.com/
This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns
ABOUT YOUR HOSTS
Dr. Jam Kothari
Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity.
Dr. Sally Moore
Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients. She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.
--------
33:07
--------
33:07
021 Understanding Risk in Myeloma: What Your Genetics Can Tell You
This episode unpacks the complex world of myeloma genetics - what high and standard risk really mean, how these tests guide treatment, and how future advances could lead to truly personalised care with Sarah Gooding.
Sarah is a colleague, and an Honorary Consultant Haematologist, based in Oxford.
📌Key Takeaways:
Your myeloma is unique - genetic tests help doctors understand how it may behave and respond to treatment.
High-risk myeloma can still respond well to newer, more powerful therapies now being developed.
The future lies in personalised treatment - matching the right drug to each patient’s myeloma for the best outcomes.
For extra content and more resources, please visit our website: https://www.themyelomaminutes.com/
This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns
ABOUT YOUR HOSTS
Dr. Jam Kothari
Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity.
Dr. Sally Moore
Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients. She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.
--------
36:31
--------
36:31
020 Myeloma UK at the Heart: Advocacy, Research and Hope
This episode features Dr Sophie Castell, CEO of Myeloma UK, sharing insights into the charity’s vital work in research, advocacy, patient support, and tackling inequalities in myeloma care.
📌Key Takeaways:
Survival rates for myeloma have quadrupled — and living well is now as important as living longer.
Myeloma UK drives progress from early diagnosis to survivorship, always keeping patients’ voices central.
The new “Knowledge is Power” campaign tackles inequalities, raising awareness in communities most affected.
For extra content and more resources, please visit our website: https://www.themyelomaminutes.com/
This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns
ABOUT YOUR HOSTS
Dr. Jam Kothari
Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity.
Dr. Sally Moore
Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients. She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.
--------
37:47
--------
37:47
019 Four Drugs, One Goal - A New Option for Older Myeloma Patients
Welcome to The Myeloma Minutes. We've now moved to a fortnightly release schedule, so you can now hear us every-other Thursday.
This episode explains the newly approved four-drug treatment (Isatuximab, Velcade, Lenalidomide and Dexamethasone) for older people with myeloma who are not eligible for a stem cell transplant.
📌Key Takeaways:
This four-drug ‘quadruplet’ can keep myeloma under control for many years — even in older patients.
Each drug works differently, combining to give stronger and longer remissions.
Side effects like infection, neuropathy or diarrhoea are real — but doses can be tailored to keep patients well.
This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns
ABOUT YOUR HOSTS
Dr. Jam Kothari
Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity.
Dr. Sally Moore
Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients. She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.
UK